Welcome!

News Feed Item

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/689745/Sickle-Cell-Disease-Global-Clinical-Trials-Review-H2-2014.html

Sickle Cell Disease Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Sickle Cell Disease Global Clinical Trials Review, H2, 2014" provides data on the Sickle Cell Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sickle Cell Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sickle Cell Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Sickle Cell Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Sickle Cell Disease 25
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Sickle Cell Disease Therapeutics Clinical Trials 33
Prominent Drugs 35
Latest Clinical Trials News on Sickle Cell Disease 36
Jun 16, 2014: Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial 36
Clinical Trial Profiles 37
Clinical Trial Overview of Top Companies 37
Novartis AG 37
Clinical Trial Overview of Novartis AG 37
Eli Lilly and Company 38
Clinical Trial Overview of Eli Lilly and Company 38
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Prolong Pharmaceuticals 40
Clinical Trial Overview of Prolong Pharmaceuticals 40
HemaQuest Pharmaceuticals, Inc. 41
Clinical Trial Overview of HemaQuest Pharmaceuticals, Inc. 41
Selexys Pharmaceuticals Corporation 42
Clinical Trial Overview of Selexys Pharmaceuticals Corporation 42
Ikaria Inc. 43
Clinical Trial Overview of Ikaria Inc. 43
Emmaus Life Sciences, Inc. 44
Clinical Trial Overview of Emmaus Life Sciences, Inc. 44
Baxter International Inc. 45
Clinical Trial Overview of Baxter International Inc. 45
Clinical Trial Overview of Top Institutes / Government 46
National Heart, Lung, and Blood Institute 46
Clinical Trial Overview of National Heart, Lung, and Blood Institute 46
Assistance Publique - Hopitaux de Paris 49
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 49
HaEmek Medical Center 50
Clinical Trial Overview of HaEmek Medical Center 50
Cincinnati Children's Hospital Medical Center 51
Clinical Trial Overview of Cincinnati Children's Hospital Medical Center 51
Duke University 52
Clinical Trial Overview of Duke University 52
Emory University 53
Clinical Trial Overview of Emory University 53
National Institutes of Health Clinical Center 54
Clinical Trial Overview of National Institutes of Health Clinical Center 54
Baylor College of Medicine 55
Clinical Trial Overview of Baylor College of Medicine 55
Children's Hospital & Research Center Oakland 56
Clinical Trial Overview of Children's Hospital & Research Center Oakland 56
Five Key Clinical Profiles 57
Appendix 99
Abbreviations 99
Definitions 99
Research Methodology 100
Secondary Research 101
About GlobalData 101
Contact Us 101
Disclaimer 101
Source 102

List of Tables
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region, 2014* 7
Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Sickle Cell Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, G7 Countries (%), 2014* 15
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, E7 Countries (%), 2014* 18
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Sickle Cell Disease Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Sickle Cell Disease Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Sickle Cell Disease Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 31
Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 37
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 38
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 39
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Prolong Pharmaceuticals, 2014* 40
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by HemaQuest Pharmaceuticals, Inc., 2014* 41
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Selexys Pharmaceuticals Corporation, 2014* 42
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Ikaria Inc., 2014* 43
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Emmaus Life Sciences, Inc., 2014* 44
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Baxter International Inc., 2014* 45
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 46
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 49
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by HaEmek Medical Center, 2014* 50
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Cincinnati Children's Hospital Medical Center, 2014* 51
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 52
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 53
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institutes of Health Clinical Center, 2014* 54
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2014* 55
Sickle Cell Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Hospital & Research Center Oakland, 2014* 56

List of Figures
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Sickle Cell Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Sickle Cell Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Sickle Cell Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Sickle Cell Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Sickle Cell Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Sickle Cell Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, G7 Countries (%), 2014* 15
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Sickle Cell Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Sickle Cell Disease to Hematological Disorders Clinical Trials, E7 Countries (%), 2014* 18
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Sickle Cell Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Sickle Cell Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Sickle Cell Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Sickle Cell Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Sickle Cell Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Sickle Cell Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 31
Sickle Cell Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Sickle Cell Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Sickle Cell Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
GlobalData Methodology 100

Read the full report:
Sickle Cell Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/689745/Sickle-Cell-Disease-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
SYS-CON Events announced today that Massive Networks, that helps your business operate seamlessly with fast, reliable, and secure internet and network solutions, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. As a premier telecommunications provider, Massive Networks is headquartered out of Louisville, Colorado. With years of experience under their belt, their team of...
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, will discuss how from store operations...
Though cloud is the future of enterprise computing, a smooth transition of legacy applications and systems is critical for seamless business operations. IT professionals are eager to start leveraging the cost, scale and other benefits of cloud, but with massive investments already in place in existing infrastructure and a number of compliance and resource hurdles, it can be challenging to move to a cloud-based infrastructure.
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, will go over the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, applicatio...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, will lead you through the exciting evolution of the cloud. He'll look at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering ...
Infoblox delivers Actionable Network Intelligence to enterprise, government, and service provider customers around the world. They are the industry leader in DNS, DHCP, and IP address management, the category known as DDI. We empower thousands of organizations to control and secure their networks from the core-enabling them to increase efficiency and visibility, improve customer service, and meet compliance requirements.
In his session at 21st Cloud Expo, Michael Burley, a Senior Business Development Executive in IT Services at NetApp, will describe how NetApp designed a three-year program of work to migrate 25PB of a major telco's enterprise data to a new STaaS platform, and then secured a long-term contract to manage and operate the platform. This significant program blended the best of NetApp’s solutions and services capabilities to enable this telco’s successful adoption of private cloud storage and launchi...
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
Transforming cloud-based data into a reportable format can be a very expensive, time-intensive and complex operation. As a SaaS platform with more than 30 million global users, Cornerstone OnDemand’s challenge was to create a scalable solution that would improve the time it took customers to access their user data. Our Real-Time Data Warehouse (RTDW) process vastly reduced data time-to-availability from 24 hours to just 10 minutes. In his session at 21st Cloud Expo, Mark Goldin, Chief Technolo...